380 related articles for article (PubMed ID: 16724367)
21. Update on the mechanisms and efficacy of biological therapies for psoriasis.
Koo J; Khera P
J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
[TBL] [Abstract][Full Text] [Related]
22. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
Katugampola RP; Lewis VJ; Finlay AY
Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
[TBL] [Abstract][Full Text] [Related]
23. Biological agents in the treatment of psoriasis.
Tzu J; Krulig E; Cardenas V; Kerdel FA
G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
[TBL] [Abstract][Full Text] [Related]
25. A new era in the management of psoriasis? The biologics: facts and controversies.
Ferrándiz C; Carrascosa JM; Boada A
Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
[TBL] [Abstract][Full Text] [Related]
26. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.
Tutrone WD; Saini R; Weinberg JM
IDrugs; 2004 Jan; 7(1):45-9. PubMed ID: 14730466
[TBL] [Abstract][Full Text] [Related]
27. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
[TBL] [Abstract][Full Text] [Related]
28. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
30. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
31. Overview of biologic agents in medicine and dermatology.
Sobell JM
Semin Cutan Med Surg; 2005 Mar; 24(1):2-9. PubMed ID: 15900793
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
Sobell JM; Hallas SJ
Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
34. Nail psoriasis and biologics.
Noiles K; Vender R
J Cutan Med Surg; 2009; 13(1):1-5. PubMed ID: 19298765
[TBL] [Abstract][Full Text] [Related]
35. [Biologic therapy: a new and promising option to treat psoriasis].
Espinoza-González NA; Herz-Ruelas M; Ocampo-Candiani J; González-Soto R
Rev Med Inst Mex Seguro Soc; 2008; 46(4):405-14. PubMed ID: 19213212
[TBL] [Abstract][Full Text] [Related]
36. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
38. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
Leon A; Nguyen A; Letsinger J; Koo J
Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017
[TBL] [Abstract][Full Text] [Related]
39. The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
Clark L; Lebwohl M
J Am Acad Dermatol; 2008 Mar; 58(3):443-6. PubMed ID: 18083274
[TBL] [Abstract][Full Text] [Related]
40. Biological therapy and nail psoriasis.
Lawry M
Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]